Back to results
US 2024/0325537 A1Published application
Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsGreg M. Delgoffe, Ronal Peralta
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions, including modified peripheral blood mononuclear cells (PBMCs) with reduced expression of Slc16a11 and/or reduced activity of MCT11. Also provided are siRNAs and gRNAs targeting Slc16a11. Methods of using the disclosed compositions in the treatment of cancer are also provided.
Claims28
A modified peripheral blood mononuclear cell (PBMC) with reduced expression of Slc16a11, reduced activity of MCT11, or both, wherein the modified PBMC comprises:
- 1) an agent that reduces Slc16a11 expression;
- or
- 2) a non-naturally occurring genetic modification that reduces an amount of functional MCT11.
(canceled)
9-10. (canceled)
19-25. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.